~ Elimination of Hepatitis C as a Public
Health Threat is Possible ~
MISSISSAUGA, ON, May 28, 2019 /CNW/ - In support of Canada's
commitment to the World Health Organization's (WHO) goal of
eliminating hepatitis C (HCV) infection by 2030, Gilead Sciences
Canada, Inc. (Gilead Canada) today
announced the awarding of HCV Micro-Elimination Grants. The intent
of the grants is to support local initiatives across the country to
help identify people with chronic HCV and link them to care and
treatment. This year, 11 projects have been selected to
connect to care some of the most difficult-to-reach high-risk
populations for HCV, including people who are: injecting drugs,
economically disadvantaged/homeless, co-infected with HIV,
immigrants/refugees, formerly incarcerated, and sex
workers.1 Launched in 2018, Gilead Canada has awarded a total of 25 grants
to date.
St. Michael's Hospital Academic
Family Health Team in Toronto is
one of this year's grant recipients. Many of the 45,000
patients across its six downtown sites come from diverse
backgrounds with an increased risk of HCV, including new
immigrants, people living in poverty, those who are homeless,
people co-infected with HIV and people struggling with mental
health and addictions.
"We realized that about 40 per cent of our patients with HCV had
not accessed life-saving treatment, and that was a wake-up call for
us. Our goal now is to cure hepatitis C in our practice,"
said Dr. Tara Kiran, staff physician
at St. Michael's Hospital Academic
Family Health Team. "By educating family doctors to treat
patients with HCV, we will be able to cure more patients and
contribute to the elimination of the disease."
Dr. Edward Tam, Medical Director,
LAIR Centre in Vancouver, and also
a 2019 grant recipient, will look to develop a new model of care to
support people diagnosed with HCV at the same time that they are
being treated for addiction issues. Working with Dr.
Jay Wortman, Medical Director, Royal
Oak Clinic in Vancouver, the grant
will help to identify clinic patients undergoing opiate agonist
therapy for addictions who also have HCV, and provide treatment and
support in one setting.
"Many prescribers of opiate agonist therapy for people with
addiction issues are not familiar with the treatment of HCV, and it
is unrealistic to expect that these patients will find their way to
a second specialist to access and treat their HCV," said Dr.
Tam. "We need to do more to facilitate simultaneous treatment
of addictions and HCV at one time and one place. We
anticipate that this mandate will prove to be a viable and powerful
strategy to advance HCV elimination efforts."
"We recognize that it will take more than just science to
eliminate the burden of HCV on patients, our health system and
Canadian society as a whole," said Kennet Brysting, General Manager
of Gilead Canada. "Together
with our grant recipients, we can take collective steps to
establish effective HCV micro-elimination strategies and programs
right here in Canada that can
contribute to the worldwide elimination of HCV. We are
already seeing positive results from last year's micro-elimination
efforts."
2018 Mandate Treats 193 Difficult-to-Reach People in Quebec
City Region
After receiving a grant in 2018, the Coopérative
de solidarité SABSA in Quebec City
identified vulnerable people with HCV in the region, including
people who inject drugs, people with mental health issues, or
people who have experienced homelessness. SABSA also provided
care to patients, including support to attend medical appointments
and needs around housing, nutrition and therapy, to help ensure
patient retention and treatment adherence. In total, SABSA
surpassed its goals and identified 220 people with HCV and linked
193 people to care.
2019 HCV Micro-Elimination Grant Recipients
Grant
recipients were selected based on their ability to demonstrate a
plan to deliver new local micro-elimination projects focused on
targeted, integrated and locally-based initiatives, in high
prevalence areas or settings that increase HCV prevention,
screening, diagnosis and linkage to care. The full list of
2019 HCV Micro-Elimination Grant recipients in Canada includes:
Organization: LAIR Centre (Vancouver,
BC)
Project Title: "Eliminate C in OAT" (Opiate Agonist Therapy)
Primary Patient Population: Addiction/substance use
Organization: Cool Aid Community Health Centre (Victoria, BC)
Project Title: "INHOME"
Primary Patient Population: HCV/HIV co-infection
Organization: Community Based Research Centre Society
(Vancouver, BC)
Project Title: "The Feasibility and Acceptability of Online
Screening, At-Home Dried Blood Spot Collection, and Peer-Based
Linkage to Care for HCV Micro-Elimination in British Columbia"
Primary Patient Population: HCV/HIV co-infection
Organization: St. Michael's
Hospital Academic Family Health Team (Toronto, ON)
Project Title: "Micro-Elimination of Hepatitis C in a High-Risk
Urban Family Health Team by Providing Support for Primary Care
Providers to Scale Up Treatment"
Primary Patient Population: Vulnerable patients within its clinic
sites
Organization: Réseau ACCESS Network (Sudbury, ON)
Project Title: "The Sudbury/Manitoulin Micro-Elimination
Project"
Primary Patient Population: People who inject drugs
Organization: Kitchenuhmaykoosib Inninuwug (Big Trout Lake, ON)
Project Title: "The Elimination of Hepatitis C Infection in
Kitchenuhmaykoosib Inninuwug First Nation"
Primary Patient Population: Indigenous
Organization: Dalhousie Healing Support Fund (Toronto, ON)
Project Title: "Telemedicine Enhanced Expanded Medical Access
Partnership:
An Innovative Approach to Micro-Elimination"
Primary Patient Population: Substance use
Organization: Dopamine (Montreal,
QC)
Project Title: "Dopamed and HCV Micro-Elimination"
Primary Patient Population: People who inject drugs
Organization: Centre L'Envolée de Granby (Shefford,
QC)
Project Title: "Micro-Elimination of Hepatitis C Among the
Incarcerated/Formerly Incarcerated"
Primary Patient Population: Prisoners
Organization: Street Pact Inc./Pacte de Rue Inc.
(Salaberry-de-Valleyfield, QC)
Project Title: "Street Doctor and Community Care Project"
Primary Patient Population: People who inject drugs
Organization: CAPAHC – Hepatitis C Multipurpose Assisted
Clinic (Montreal, QC)
Project Title: "HCV Screening in the Pakistani Community in
Montreal"
Primary Patient Population: Immigrant
About HCV Micro-Elimination
Micro-elimination is a
concept that involves eliminating HCV within defined segments of
the population in order to incrementally achieve national
elimination. Micro-elimination is a pragmatic way to
establish realistic elimination goals, allocate resources and
support local expertise to tailor, deliver and scale up
interventions. Segments of the population that can be
targeted for micro-elimination can include people in certain
settings, geographic areas, subpopulations and age cohorts, for
example people in prisons, or people living with co-infections such
as HIV.2
About HCV in Canada
In Canada, it is estimated that
290,000 Canadians are living with chronic HCV and thousands of new
cases are diagnosed each year.3 Around 44 per cent
of people living with chronic HCV infection are unaware of their
status.4 There are six genotypes of HCV.
Left untreated, HCV can progress into a serious medical condition
that may result in cirrhosis, cancer and other life-threatening
complications. Populations at increased risk of HCV infection
include: people who inject drugs, Baby Boomers born between
1945-1975, recipients of infected blood products or invasive
procedures in healthcare facilities with inadequate infection
control practices, people with sexual partners who are
infected with HCV, people with HIV infection, prisoners or
previously incarcerated persons, and people who have had
tattoos or piercings.5
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that
discovers, develops and commercializes innovative therapeutics in
areas of unmet medical need. The company's mission is to
advance the care of patients suffering from life-threatening
diseases. Gilead has operations in more than 35 countries
worldwide, with headquarters in Foster
City, California. Gilead Sciences Canada, Inc. is the
Canadian affiliate of Gilead Sciences, Inc., and was established in
Mississauga, Ontario, in 2006.
For more information on Gilead Sciences,
please visit the company's website at www.gilead.com, follow Gilead
on Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or
1-650-574-3000.
________________________________
1. World Health Organization. Hepatitis C Fact Sheet. Updated
October 2017.
2. CATIE:
https://www.catie.ca/en/pif/spring-2019/micro-elimination-hepatitis-c-pathway-achieve-national-elimination-goals
3. Institute for Health Metrics and Evaluation. IHME
Hepatitis Facts. IHME. Accessed August 3, 2018.
4. Public Health Agency of Canada. Report on Hepatitis B and
C in Canada: 2014.
5. World Health Organization. Hepatitis C Fact Sheet. Updated
October 2017.
|
SOURCE Gilead Sciences, Inc.